Codeine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Codeine: From Analgesic/Antitussive Use to Nasal Cavity Disease
One-Sentence Summary
Codeine is an opioid historically used as an analgesic and antitussive (cough suppressant); no original indication or approval record is present in this Evidence Pack, and detailed mechanism-of-action data is a confirmed data gap. TxGNN predicts a possible link to Nasal Cavity Disease with a very high score, but the only supporting literature (2 case reports) describes intranasal opioid abuse causing tissue necrosis and rhinolithiasis — i.e., harm, not therapeutic benefit — and no clinical trials exist for this pairing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this Evidence Pack (Codeine is generally known as an opioid analgesic/antitussive; DG002 flags MOA as a data gap) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 (2 case reports only; no trials, no mechanistic support) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Codeine is not available in this Evidence Pack (DG002, High severity). Based on general pharmacological knowledge, Codeine is a mu-opioid agonist used systemically for pain and centrally to suppress cough — neither mechanism has an established link to primary nasal cavity pathology.
Critically, the literature returned for this pairing does not support a therapeutic hypothesis. Both PubMed hits (PMID 22965281, PMID 17315836) describe intranasal abuse of opioid-containing products causing tissue necrosis, rhinolithiasis, and a foreign-body “opioma” — these are adverse/toxic events, not evidence of treatment efficacy. One of the two reports concerns hydrocodone-acetaminophen, not Codeine itself, further weakening the direct evidence base.
The TxGNN score of 99.93% most likely reflects a co-occurrence artifact (Codeine and nasal-cavity terms appear together in adverse-event literature) rather than a genuine repurposing signal. The same pattern repeats across the other top-ranked predictions in this pack: acute laryngopharyngitis (L5, no evidence at all), trigeminal autonomic cephalalgia (L4, headache-society guidance explicitly discourages opioids), and allergic urticaria (L4, literature shows Codeine causes mast-cell degranulation/urticaria rather than treating it). All four were independently scored “Hold” in the source evidence pack.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22965281 | 2012 | Case report | The Laryngoscope | Intranasal hydrocodone-acetaminophen abuse caused necrosis of the nasal cavity and pharynx — adverse event, not therapeutic use |
| 17315836 | 2007 | Case report | Ear, Nose & Throat Journal | Rhinolithiasis (“opioma”) formed around an impacted mixture of codeine and opium in the nasal cavity — foreign-body/toxicity case, not treatment evidence |
India Market Information
No registration records available — Codeine is currently not marketed in this jurisdiction under this Evidence Pack (0 licenses on file).
Safety Considerations
- Drug Interactions: Database query returned 449 total interactions. Notable examples include Major-level interactions with Alvimopan and Bupropion, and Moderate-level interactions with Atropine, Cimetidine, Dexamethasone, Dronabinol, Eliglustat, Eluxadoline, Glycopyrronium, Granisetron, Hyoscyamine, and Loperamide, among others (source: DDInter).
Key warnings and contraindications from the local product label are not yet available (DG001, Blocking severity) — please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication is supported only by two case reports describing opioid-related nasal tissue injury, not therapeutic benefit — the mechanistic direction is inverted relative to what would justify repurposing. This pattern holds across all four top predictions in the pack, none of which have supporting trials or a coherent MOA-to-indication rationale. Codeine is also not currently marketed in this jurisdiction, and label-level safety data (DG001) is a blocking gap.
To proceed, the following is needed:
- TFDA/local package insert data (warnings, contraindications) — currently blocking
- Confirmed mechanism of action from DrugBank or primary literature
- Re-evaluation of TxGNN candidate list against literature co-occurrence bias (adverse-event mentions should be filtered from training/scoring)
- If any indication is pursued further, dedicated preclinical or observational evidence specific to a therapeutic (not toxic) relationship
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.